Abstract: The present disclosure provides a composition containing an iridium complex represented by general formula (1) below and a halogen atom. The content of the halogen atom is less than 5 ppm. In general formula (1), R8 to R20 are each a hydrogen atom or a substituent. R14 is an electron-withdrawing substituent having a Hammett constant ?m of 0.3 or more, and R1 to R7 are each a hydrogen atom or a methyl group.

Abstract: A white toner including toner particles each of which contains a binder resin and a white pigment whose content is 20 to 80 mass % or less, wherein the binder resin contains a polymer A having a first and a second monomer unit, wherein the content of the first monomer unit is 5.0 to 60.0 mol % with respect to the total number of moles of all monomer units in the polymer A, wherein the content of the second monomer unit is 20.0 to 95.0 mol % with respect to the total number of moles of all the monomer units in the polymer A, wherein the SP value of the first monomer unit and the SP value of the second monomer unit satisfy specific relations, and wherein the white pigment has a total amount of a surface acidic group amount and a surface basic group amount of 60 ?mol/g or more.

Abstract: A composition that includes: a homo-N-trans (HNT) iridium complex having an iridium atom, and a first ligand, a second ligand, and a third ligand that are bonded to the iridium atom, the second ligand having the same structure as the first ligand, the third ligand having a different structure from the first and second ligands; and an isomer of the iridium complex, the isomer having an iridium atom, a fourth ligand, a fifth ligand, and the third ligand, the fourth ligand being a ligand represented by the same rational formula as that of the first ligand, and the fifth ligand being a ligand represented by the same rational formula as that of the second ligand. The composition ratio of the isomer relative to a total of the iridium complex and the isomer is 1.5% or more.

Abstract: A composition that contains an iridium complex and an isomer of the iridium complex, in which the amount of the isomer of the iridium complex is decreased. The iridium complex is a homo-N-trans (HNT) iridium complex having an iridium atom, and a first ligand, a second ligand, and a third ligand that are bonded to the iridium atom. The isomer has an iridium atom, a fourth ligand, a fifth ligand, and the third ligand. The composition ratio of the isomer relative to a total of the iridium complex and the isomer is 1.0% or less.

Abstract: A white toner including toner particles each of which contains a binder resin and a white pigment whose content is 20 to 80 mass % or less, wherein the binder resin contains a polymer A having a first and a second monomer unit, wherein the content of the first monomer unit is 5.0 to 60.0 mol % with respect to the total number of moles of all monomer units in the polymer A, wherein the content of the second monomer unit is 20.0 to 95.0 mol % with respect to the total number of moles of all the monomer units in the polymer A, wherein the SP value of the first monomer unit and the SP value of the second monomer unit satisfy specific relations, and wherein the white pigment has a total amount of a surface acidic group amount and a surface basic group amount of 60 ?mol/g or more.

Abstract: The present invention provides a method of determining a lung cancer treatment, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining the treatment based on the amount of KL-6 measured, and a method of determining the effectiveness of an agent for treatment of lung cancer on a subject, the method comprising: measuring an amount of KL-6 in a sample of body fluid from the subject, determining the effectiveness of an EGFR inhibitor on the subject should the EGFR inhibitor be administered as the agent for treatment of lung cancer, based on the amount of KL-6 measured.